2026-04-18T00:22:59Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4649422025-08-31T15:52:54Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc García-Melendo, Cristina author Cubiró, Xavier author Puig Sanz, Lluís author Universitat Autònoma de Barcelona author 2021 Dermatologists' interest in the Janus-associated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway has been growing as evidence builds to support its key role in the pathogenesis of inflammatory skin diseases. Because certain proinflammatory cytokines use the JAK/STAT pathway for signal transduction, it has become a promising therapeutic target in diseases where selective modulation of the immune system can be useful. We aim to review current knowledge of the JAK/STAT signaling pathway and its role in immune-mediated skin diseases. In the second part of the review we cover the efficacy and safety of oral and topical JAK inhibitors in the treatment of psoriasis, atopic dermatitis, and other skin diseases. JAK/STAT pathway Janus kinase inhibitors Psoriasis Atopic dermatitis Janus Kinase Inhibitors in Dermatology : Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses Inhibidores de JAK: usos en dermatología. Parte 2: aplicaciones en psoriasis, dermatitis atópica y otras dermatosis